Esperion Therapeutics (ESPR) PT Raised to $7 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ESPR Hot Sheet
Price: $3.18 --0%
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
JPMorgan analyst Jessica Fye raised the price target on Esperion Therapeutics (NASDAQ: ESPR) to $7.00 (from $6.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- Freshworks Inc (FRSH) PT Raised to $17 at UBS
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
